Advertisement
Advertisement
Start-ups
Get more with myNEWS
A personalised news feed of stories that matter to you
Learn more
Billionaire tech entrepreneur Elon Musk, chief executive of Tesla, speaks at the VivaTech fair in Paris, France, on June 16, 2023. Musk said start-up Neuralink would carry out its first brain-chip implant on a human later this year. Photo: Bloomberg

Elon Musk expects brain chip start-up Neuralink to start its first human trial later this year after receiving US government approval

  • Neuralink co-founder Elon Musk said the company plans to implant a tetraplegic or paraplegic patient
  • The US Food and Drug Administration has cleared the start-up for its first-in-human clinical trial, despite an investigation over animal experiments
Start-ups
Billionaire technology entrepreneur Elon Musk expects his brain-chip start-up Neuralink to start its first human trial this year, he said on Friday in France.

Speaking at the VivaTech event in Paris, Neuralink co-founder Musk said the company plans to implant a tetraplegic or paraplegic patient during a webcast monitored by Reuters.

While he did not specify how many patients his company would implant or for how long, “it’s looking like the first case will be later this year”, said Musk, who is also chief executive of electric carmaker Tesla and rocket launch company Space Exploration Technologies Corp. Earlier this month, Musk stepped down as head of social media platform Twitter.
Last month, Neuralink said it received US Food and Drug Administration (FDA) clearance for its first-in-human clinical trial, a critical milestone for the start-up as it faces an investigation in the country over its handling of animal experiments.
This video grab made from the online Neuralink live stream on August 28, 2020, shows the start-up’s disk implant held by company co-founder Elon Musk during the online presentation. Photo: Agence France-Presse

The FDA acknowledged in an earlier statement to Reuters that the agency cleared Neuralink to use its brain implant and surgical robot for trials, but declined to provide more details.

If Neuralink can prove its device is safe in humans, it would still take several years – potentially more than a decade – for the start-up to secure commercial-use clearance, experts earlier told Reuters. The company is also competing with other neurotech companies which have already implanted their devices in people.

Musk, however, has missed timelines on his public pronouncements about Neuralink before. On at least four occasions since 2019, Musk predicted that Neuralink would soon start human trials.

Neuralink, founded in 2016, first sought permission from the FDA early last year, and the agency rejected the application, citing dozens of safety concerns, Reuters has reported. Some of the issues involved the lithium battery of the device, the possibility of the implant’s wires migrating within the brain and the challenge of safely extracting the device without damaging brain tissue.

This video grab from the online Neuralink live stream on August 28, 2020, shows company co-founder Elon Musk standing next to the start-up’s surgical robot. Photo: Agence France-Presse

Neuralink also faces federal scrutiny, following Reuters reports about its animal experiments.

Last year, Neuralink employees told Reuters the company was rushing and botching surgeries on monkeys, pigs and sheep, resulting in more animal deaths than necessary, as Musk pressured staff to receive FDA approval. The animal experiments produced data intended to support the company’s application for human trials, the sources said.

In one instance in 2021, the company implanted 25 out of 60 pigs with the wrong-sized devices. All the pigs were subsequently killed – an error that employees said could have been easily avoided with more preparation.

In May, US lawmakers urged regulators to investigate whether the make-up of Neuralink’s panel overseeing animal testing contributed to botched and rushed experiments after Reuters reported on potential financial conflicts on the board.

The US Department of Transportation is separately investigating whether Neuralink illegally transported dangerous pathogens on chips removed from monkey brains without proper containment measures. An agency representative said on Friday the investigation is ongoing.

Neuralink has also been under investigation by the US Department of Agriculture’s (USDA) Office of Inspector General for potential animal-welfare violations. This inquiry has been looking at the USDA’s oversight of Neuralink. An agency representative did not immediately respond to a comment request.

Meanwhile, Neuralink’s valuation has shot up in recent months. The start-up was valued at close to US$2 billion in a private fundraising round two years ago and is now worth around US$5 billion based on privately executed stock trades, Reuters reported this month.

Neuralink employees who sat on the company’s animal board, which has come under federal scrutiny for potential financial conflicts, stood to benefit from the implant’s quick development. Neuralink stock that some of the employees hold has jumped around 150 per cent in value in just two years, based on the secondary trades, Reuters reported.

Post